BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025
BioNTech (Nasdaq: BNTX) will release its third quarter 2025 financial results on Monday, November 3, 2025. A live conference call and webcast for investors, analysts and the public will be held at 8:00 a.m. EST (2:00 p.m. CET) to discuss results and provide a corporate update.
Participants must register in advance to access telephone dial‑in numbers and a PIN; registration is recommended at least one day before the call. The slide presentation and live audio will be available on BioNTech's Investor Relations "Events & Presentations" page at www.BioNTech.com. A replay will be archived on the company website for 30 days after the call.
BioNTech (Nasdaq: BNTX) will release its third quarter 2025 financial results on Monday, November 3, 2025. A live conference call and webcast for investors, analysts and the public will be held at 8:00 a.m. EST (14:00 CET) to discuss results and provide a corporate update.
Participants must register in advance to access telephone dial‑in numbers and a PIN; registration is recommended at least one day before the call. The slide presentation and live audio will be available on BioNTech's Investor Relations "Events & Presentations" page at www.BioNTech.com. A replay will be archived on the company website for 30 days after the call.
BioNTech (Nasdaq: BNTX) publicará sus resultados financieros del tercer trimestre de 2025 el lunes 3 de noviembre de 2025. Una conferencia telefónica en vivo y un webcast para inversores, analistas y el público se realizarán a las 8:00 a.m. EST (14:00 CET) para discutir los resultados y proporcionar una actualización corporativa.
Los participantes deben registrarse con anticipación para acceder a los números de marcación telefónica y a un PIN; se recomienda registrarse al menos un día antes de la llamada. La presentación de diapositivas y el audio en vivo estarán disponibles en la página de "Eventos y Presentaciones" de Relaciones con Inversores de BioNTech en www.BioNTech.com. Una reproducción quedará archivada en el sitio web de la compañía durante 30 días después de la llamada.
BioNTech (나스닥: BNTX)는 2025년 3분기 재무 실적을 2025년 11월 3일 월요일에 발표합니다. 투자자, 애널리스트 및 일반 대중을 위한 라이브 컨퍼런스콜 및 웹캐스트는 동부 표준시 8:00(중부유럽 표준시 14:00)에 개최되어 결과를 논의하고 기업 업데이트를 제공합니다.
참가자는 전화 다이얼 인 번호와 PIN에 접근하기 위해 사전에 등록해야 합니다. 등록은 통화 하루 전까지 권장됩니다. 슬라이드 프리젠테이션과 라이브 오디오는 BioNTech의 투자자 관계 '이벤트 및 프리젠테이션' 페이지 www.BioNTech.com에서 이용 가능하며, 통화 후 30일간 회사 웹사이트에 재생본이 보관됩니다.
BioNTech (NASDAQ : BNTX) publiera ses résultats financiers du troisième trimestre 2025 le lundi 3 novembre 2025. Une conférence téléphonique en direct et un webcast destinés aux investisseurs, aux analystes et au grand public auront lieu à 8h00 EST (14h00 CET) pour discuter des résultats et fournir une mise à jour de l'entreprise.
Les participants doivent s'inscrire à l'avance pour accéder aux numéros d'appel et à un code PIN; l'inscription est recommandée au moins un jour avant l'appel. La présentation des diapositives et l'audio en direct seront disponibles sur la page des « Événements et présentations » des Relations investisseurs BioNTech sur www.BioNTech.com. Une rediffusion sera archivée sur le site Web de l'entreprise pendant 30 jours après l'appel.
BioNTech (Nasdaq: BNTX) wird am Montag, dem 3. November 2025, seine Finanzergebnisse des dritten Quartals 2025 veröffentlichen. Eine Live-Konferenzschaltung und ein Webcast für Investoren, Analysten und die Öffentlichkeit finden um 8:00 Uhr EST (14:00 Uhr CET) statt, um Ergebnisse zu besprechen und ein Unternehmensupdate zu geben.
Teilnehmer müssen sich im Voraus registrieren, um Zugang zu Telefondial-In-Nummern und einer PIN zu erhalten; eine Registrierung wird mindestens einen Tag vor dem Anruf empfohlen. Die Folienpräsentation und das Live-Audio stehen auf der BioNTech Investor Relations-Seite „Events & Presentations“ unter www.BioNTech.com zur Verfügung. Eine Wiedergabe wird für 30 Tage nach dem Anruf auf der Unternehmenswebsite archiviert.
BioNTech (نوتسداك: BNTX) ستصدر نتائجها المالية للربع الثالث من 2025 يوم الاثنين 3 نوفمبر 2025. ستُعقد مؤتمَر هاتفي مباشر وبث ويب للمستثمرين والمحللين والجمهور في الساعة 8:00 صباحًا بتوقيت شرق الولايات المتحدة (2:00 ظهرًا بتوقيت وسط أوروبا) لمناقشة النتائج وتقديم تحديث مؤسسي.
يجب على المشاركين التسجيل مسبقًا للوصول إلى أرقام الاتصال ورمز PIN؛ يوصى بالتسجيل قبل يوم واحد على الأقل من المكالمة. ستكون عروض الشرائح والصوت المباشر متاحة على صفحة BioNTech للعلاقات مع المستثمرين 'الأحداث والعروض' على www.BioNTech.com. ستُخزَّن إعادة تشغيل لمدة 30 يومًا على موقع الشركة بعد المكالمة.
BioNTech（纳斯达克：BNTX） 将于 2025 年第三季度财务业绩 于 2025 年 11 月 3 日（星期一）公布。面向投资者、分析师和公众的现场电话会议和网络广播将于 美东时间 8:00（中欧时间 14:00） 举行，以讨论结果并提供公司更新。
参与者必须提前注册以访问电话拨入号码和 PIN；建议在通话前至少提前一天完成注册。幻灯片演示和现场音频将可在 BioNTech 投资者关系的“活动与演示”页面 www.BioNTech.com 上查看。回放将在通话后 30 天 在公司网站存档。
- None.
- None.
MAINZ, Germany, October 27, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2025 on Monday, November 3, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EST (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this link.
Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page in the Investor Relations section of the Company’s website at www.BioNTech.com. A replay of the webcast will be made available shortly after the call and archived on the Company’s website for 30 days following the call.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron.
For more information, please visit www.BioNTech.com.
CONTACTS
Investor Relations
Douglas Maffei, PhD
Investors@biontech.de
Media Relations
Jasmina Alatovic
Media@biontech.de
FAQ
When will BioNTech (BNTX) report third quarter 2025 results?
What time is the BioNTech (BNTX) Q3 2025 earnings call and webcast?
How do investors register for BioNTech's (BNTX) November 3, 2025 call?
Where can I find the BioNTech (BNTX) Q3 2025 presentation slides and webcast?
Will a replay of the BioNTech (BNTX) Q3 2025 webcast be available?
Who is the target audience for BioNTech's (BNTX) November 3, 2025 webcast?
